Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR") has completed the previously announced amalgamation (the "Transaction") with 1587818 B.C. Ltd. ("818"). The entity.
WELLSTAR has received conditional approval from the TSX Venture Exchange as a Tier 1 issuer, subject to satisfaction of the TSXV's customary listing conditions, and is expected to commence trading on or around October 1, 2026, under the ticker symbol "WSTR".Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to...
WELL Research is the clinical research brand of WELL Health Technologies. WELL Research offers the unique combination of full-service contract research organization (CRO) services in early-phase trials, site management organization (SMO) execution at late-stage trial sites, and bioanalytical services across every phase of clinical trials. Together, these capabilities span the full clinical trial value chain and allow sponsors and providers to enrol the right trial participants quickly and...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.